Kyntra Bio opened lower at $3.67, compared with its previous close of $3.68. In the last trading session, the stock traded between $3.61 and $3.78. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Kyntra Bio is now worth
$ 37.63
Resulting in a loss of
$ 62.37 (62.37%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
$-0.11 (-2.85%)
Day High
$3.78
Day Low
$3.61
Day Open
$3.67
Prev Close
$3.68
Volume
6,699
1W Return
-10.74%
1M Return
-41.82%
3M Return
-49.16%
6M Return
-47.43%
1Y Return
-62.37%
Fundamentals
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-67.87%
EPS (TTM)
$2.96
Investment Returns
1 Week
-10.74%
1 Month
-41.82%
3 Months
-49.16%
6 Months
-47.43%
9 Months
-54.17%
Financials
Quarterly
All values in $ Mn
2.7
Mar 25
1.3
Jun 25
1.1
Sep 25
1.3
Dec 25
3.7
Mar 26
-1.5
Jun 26
Updates
2Sep
Kyntra Bio to present at H.C. Wainwright investment conference
Kyntra Bio management presents at H.C. Wainwright conference Sept 15. CEO Thane Wettig leads company presentation at 4:00 pm ET. Live webcast and replay available on investor relations page. Pipeline includes roxadustat and FG-3246 ADC program.
2mo ago
1Sep
Kyntra Bio cuts royalty cap to $65M with $42.6M upfront payment
Kyntra Bio reduces max royalty payments from $125M to $65M. Company pays $42.6M upfront, bringing total payments to $50M. Remaining $15M cap tied to 50% of Astellas revenue excl Japan. Pro forma cash position stands at $53.1M as of June 30, 2026. Cash runway extended into fourth quarter of 2027.
2mo ago
14Aug
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate
Kyntra Bio's Q2 2026 results showed an adjusted EPS of $(4.68), missing the $(3.18) estimate. Sales of $(1.474 million) also missed expectations. Despite this, net income turned positive at $12 million due to non-operating factors, with cash reserves supporting pipeline development through 2028.
3mo ago
7Jul
Oppenheimer initiates coverage on Kyntra Bio with Outperform rating
Oppenheimer analyst Jay Olson initiated coverage on Kyntra Bio with an Outperform rating and a price target of $35, indicating a positive outlook.
4mo ago
12Jun
Kyntra Bio presents roxadustat data on LR-MDS anemia
Kyntra Bio presented Phase 3 MATTERHORN trial data at EHA 2026 showing roxadustat improved transfusion independence in LR-MDS patients, including those with ring sideroblast negative disease. The company is finalizing a pivotal Phase 3 trial protocol based on FDA feedback, with initiation expected in the second half of 2026.
5mo ago
9Jun
Rodman & Renshaw initiates coverage on Kyntra Bio with Buy rating
Rodman & Renshaw analyst Michael G. King Jr. initiated coverage on Kyntra Bio with a Buy rating and a $30 price target. The stock trades on NASDAQ under the symbol KYNB.
